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Introduction
Indolent non-Hodgkin's lymphomas (NHLs) are
lymphoproliferative disorders associated with a relatively
good prognosis and a natural course prolonged to many
years. They usually affect elderly people and the diagnosis
in 90% of cases is made in advanced clinical stage of the
disease (III and IV according to Ann Arbor). Despite
the high susceptibility of this kind of lymphomas to
chemotherapy and radiotherapy, as well as a relatively
long survival time, with the exception for early stages of
clinical progress, currently available methods do not result
in permanent cure. A majority of patients develop
successive, sometimes late relapses, progression of
histological malignancy and increasing resistance to
treatment. Follicular lymphoma (FL) is one of most
commonly diagnosed indolent lymphoma and constitutes
22% of all NHLs occurring in the world [1]. Recent
achievements in molecular biology contributed signifi-
cantly to understanding the pathology of NHLs. Over the
past few years monoclonal antibodies against antigens
present on the surface of lymphoma cells, e.g. anti-CD20,
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Indolent lymphomas are lymphoproliferative disorders with a relatively good prognosis and long-term natural history. The
patients are treated with chemo-, radio- and immunotherapy. But it is impossible to achieve curability, except for the cases in
early clinical stages. Radioimmunotherapy is composed of two different methods of treatment: immuno- and radiotherapy. It
provides a new therapeutic approach in which monoclonal antibodies directed against tumor-specific antigens are used to target
therapeutic radioisotopes to sites of disseminated disease. 90Y-Ibritumomab tiuxetan is approved for the treatment of relapsed
and refractory, follicular, low-grade NHL. The energy is deposited within 5 mm of the radiation source, which kills not only
antibody-bound cells, but also neighbouring malignant cells. The aim of this paper was to describe a 50-year old woman with
relapsed follicular lymphoma who was successfully treated with 90Y-ibritumomab tiuxetan.
Zastosowanie przeciwcia∏a monoklonalnego antyCD20 sprz´˝onego z radioizotopem
w leczeniu nawrotowego ch∏oniaka grudkowego – opis przypadku
Ch∏oniaki o przebiegu powolnym nale˝à do schorzeƒ limfoproliferacyjnych o stosunkowo dobrym rokowaniu i wieloletnim
przebiegu naturalnym. Mimo znacznej podatnoÊci tych ch∏oniaków na chemio- i radioterapi´, wzgl´dnie d∏ugiego czasu
prze˝ycia, dost´pne obecnie metody nie pozwalajà na trwa∏e wyleczenie z wyjàtkiem przypadków we wczesnych stadiach
zaawansowania klinicznego. Radioimmunoterapia jest nowà metodà leczenia nowotworów uk∏adu ch∏onnego – przeciwcia∏a
monoklonalne sprz´˝one z radioaktywnym izotopem stanowià syntez´ dwóch metod leczenia ch∏oniaków: immunoterapii
i radioterapii.
Ibritumomab tiuxetan znakowany radioizotopem [90Y] (Zevalin) jest stosowany w leczeniu doros∏ych pacjentów z opornà na
leczenie CD20+ postacià grudkowego B-komórkowego ch∏oniaka nieziarniczego lub pacjentów z nawrotem choroby po
leczeniu rituximabem. Zwiàzek ten stanowi po∏àczenie przeciwcia∏a monoklonalnego z izotopem promieniotwórczym Itr 90.
Emitowane promieniowanie β ma zasi´g 5 mm, co pozwala na zniszczenie komórek CD20+ i sàsiednich, bez uszkodzenia
otaczajàcych guz tkanek prawid∏owych. Praca jest opisem przypadku 50-letniej pacjentki z nawrotowà postacià ch∏oniaka
grudkowego, leczonà skutecznie ibritumomabem.
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(rituximab) have been widely used in the treatment of
NHLs. Monoclonal antibodies have been used in the
treatment of follicular lymphoma since late 1990’s.
Recently a number of trials have been undertaken to
increase the effectiveness of monoclonal antibodies by
combining them with radioisotopes.
90Y-Ibritumomab tiuxetan (Zevalin) is used in the
management of patients with a refractory or recurrent
(following prior rituximab treatment) form of follicular
lymphoma [2]. The product is a murine anti-CD20
monoclonal antibody (ibritumomab) linked via the linker-
chelator tiuxetan to Yttrium 90 [3]. Yttrium 90 emits
β radiation with the energy of 2.3 MeV, 5 mm path length
and half-life of 2.7 days [4]. We present a case of relapsed
FL in advanced clinical stage treated successfully with
ibritumomab.
Case report
A 50-year-old female patient was diagnosed in March
2002 with CD20(+) B-cell follicular lymphoma in IV B
clinical stage with generalized enlargement of peripheral
and retroperitoneal lymph nodes, hepatomegaly (17.2
cm) and splenomegaly (23.3x10.5 cm), as well as bone
marrow involvement (lymphoma cells constituted 46.2%).
The patient received two courses of FC therapy
(fludarabine with cyclophosphamide) and 6 courses of
CHOP (cyclophosphamine, doxorubicin, vincristine,
prednisone) combined with rituximab, which resulted in
partial remission of the disease. In May 2004 she
developed progression with splenomegaly (9x18x20 cm),
enlargement of supra- and infraclavicular lymph nodes
(the largest, 3x5 cm was observed on the right side, the
node on the left side was 3x4 cm), cervical lymph node on
the left side (1.2x2 cm), retroperitoneal periaortal lymph
nodes (the largest, in the left renal hilus, was 1.5x2.5 cm),
lymph nodes around the celiac trunk (the largest was
1x1.8 cm), iliac (the largest was on the left side, 2x4.5
cm) and inguinal lymph nodes (bilaterally, 2x3.5 cm) and
associated B symptoms: fever and sweating. Laboratory
results disclosed an active disease: ESR (50/-), CRP
(15.0 mg/l). In May 2004, following rituximab pre-
treatment, the patient was administered 90Y ibritumab
tiuxetan (Zevalin) in a reduced dose of 0.3 mCi/kg due to
thrombocytopenia (the product was obtained by the
courtesy of Schering AG). No early side effects were
observed. On the 40th day after administration of the
drug thrombocytopenia (4th degree according to WHO),
as well as leukopenia and anaemia (3rd degree according
to WHO), were observed. The patient required trans-
fusion of 10 units of platelets and 8 units of red cells.
Control MRI in September 2004 revealed a significant
regression of involved lymph nodes: the cervical lymph
node on the left side decreased to the diameter of 1 cm,
the subclavicular lymph node on the right side decreased
to 1.5x2.5 cm, the remaining lymph nodes in the chest
returned to normal size or decreased to the diameter of
less than 1 cm, the spleen decreased to the size of
7x3.5x4.5 cm, there were no enlarged lymph nodes in the
abdomen and pelvis, the iliac and inguinal lymph nodes
were not enlarged. ESR (37/-) and CRP (9.54 mg/l)
decreased. The remaining biological parameters, as well
as the blood count, were normal. Control ultrasound
examination of the abdomen performed in November
2004 revealed splenomegaly of 17.8 cm and hepatomegaly
of 14.7 cm. The remaining abdominal organs were
normal. No enlarged lymph nodes were observed. The
patient has been in partial remission for the past 8
months.
Discussion
Until this day the results of treatment of NHLs have not
been satisfactory. Relapse or progression of the disease is
observed after initial therapy in about 50% of cases of
high-grade lymphomas and in about 80% of indolent
lymphomas. Thus it seems that the effectiveness of both
conventional, as well as high dose chemotherapy, has
reached its limits. Further improvement in the treatment
of lymphomas is possible only with the use of drugs with
different mechanism of action than the typical cytotoxic
drugs. Monoclonal antibodies are such a group of
medicines. NHLs are a heterogenous group of lymphoid
malignancies, however in the Northern hemisphere over
80% of lymphomas originate from B-cell lymphocytes.
The CD20 antigen occurs in 95% of cases of B-cell
lymphomas. This antigen is expressed on pre-B-cell
lymphocytes and on mature B-cell lymphocytes. It is not
found on haemopoietic system stem cells, B-cell system
progenitor cells, plasma cells and cells of other, normal
tissues. The CD20 antigen does not internalize after
binding with an antibody, nor is it released from the cell
surface and it does not circulate in plasma in a soluble
form. This provides a rationale for the therapeutic use
of anti-CD20 epitope antibodies. Anti-CD20 particle
triggers the mechanisms of cellular lysis through antibody-
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Figure 1. Enlarged lymph nodes in the CT scan of the chest before
treatment
dependent cell cytotoxicity (ADCC) and complement
dependent cytotoxity (CDC). It also exerts a direct
antiproliferative effect on malignant cells. Multicentered
trials demonstrated from 40% to 60% of clinical
responses to rituximab monotherapy in the treatment of
recurrent and refractory lymphomas [5, 6]. The reasons of
inadequate effectiveness of rituximab are believed to be:
too low serum antibody levels, insufficient binding of the
antibody to the target cells resulting from the lack or loss
of antigen expression on the surface of lymphoma cells,
poor access of the antibody to the tumour cells (especially
in patients with bulky disease) or failure of the host’s
immune mechanisms to eliminate malignant cells bound
with the antibody [4]. A majority of the above mentioned
limitations affecting the efficacy of monoclonal antibodies
may be overcome using the methods of radioimmuno-
therapy (RIT). Lymphoma cells are inherently radio-
sensitive [7]. However, radiotherapy using an external
source of energy is not possible in the majority of
lymphomas, since the dose of irradiation necessary for
complete removal of malignant cells would be too
harmful to other tissues. For this reason radiotherapy is
applied only in the treatment of lymphomas in early
clinical stages, with a localized tumour mass, commonly
in combination with cytotoxic agents or as palliative
treatment [8]. Radioimmunotherapy combines the
benefits of radiotherapy and immunotherapy – mono-
clonal antibodies directed against tumor-specific antigens
are used to target radioisotopes to sites of disseminated
disease. Monoclonal antibody selectively kills lymphoma
cells which possess a specific antigen (eg. CD20 or CD22)
on their surface, while radiation emitted by the antibody-
bound isotope kills the neighbouring cells, including cells
inaccessible to the antibody or with insufficient antigen
expression (the cross-fire effect). Ibritumomab tiuxetan is
a murine anti-CD20 antibody linked via the linker-
chelator tiuxetan to Yttrium 90. Numerous clinical trials
have confirmed the effectiveness of 90Y ibritumomab
tiuxetan in the treatment of recurrent or refractory NHLs.
After 90Y-ibritumomab tiuxetan administration patients
suffering from follicular lymphomas revealed an overall
response rate (ORR) of 82%, including 26% CR
(complete response). The results were slightly less
promising in the group with more aggressive lymphomas
– OR was observed in 43% of patients, including 29%
CR [9]. The use of 90Y-ibritumomab tiuxetan in patients
with follicular lymphoma resistant to rituximab resulted
ORR of 74%, including 15% CR [10]. In recurrent or
refractory indolent lymphomas ibritumomab results in
statistically higher ORR than rituximab (80% versus
56%), including complete/incomplete remission rate (34%
versus 20%) [11]. In the years 1996-1999 four clinical
trials involving 211 patients with B-cell NHL (including
153 with FL – 73%) were performed. Responding patients
with time to progression (TTP) of 12 months were
identified as long-term responding (LTR). Long-term
responses were achieved in 37% of all patients and 39%
of patients with FL [12].
Side effects of 90Y-ibritumomab tiuxetan include
myelosuppression, which is proportional to the degree
of bone marrow infiltration by lymphoma cells. For this
reason the drug should not be administered to patients in
whom bone marrow infiltration exceeds 25%. The toxic
effect of ibritumomab on the haematopoietic system
is reversible. Its main manifestation is thrombocyto-
penia, therefore patients with mild thrombocytopenia
(100-150 G/l) receive reduced doses of the drug
(0.3 mCi/kg). The effectiveness and safety of the reduced
dose was evidenced in trials (ORR of 83%, including
47% CR and CRu, mean TTP was 9,4 months and in
patients with CR/CRu – 24.5 months) [13]. About 2% of
patients develop human antimouse antibody (HAMA)
in response to RIT. Studies show that the percentage of
secondary malignancies in patients with RIT is lower than
after conventional chemotherapy.
Optimum application of radioimmunotherapy still
remains the subject of clinical trials. Ongoing studies
investigate the use of ibritumomab in the initial treatment
of the disease: in a group of 10 patients with FL in III or
IV clinical stage who required treatment, 8 responses
were obtained including 5 CR (62%) and 3 PR (partial
response) (38%) [14]. Other trials are aimed at increasing
the effectiveness of therapy by several administrations of
the drug, increasing the dose, combining radioimmuno-
therapy with chemo and/or megachemotherapy. If the
disease relapses after administration of 90Y-ibritumomab
tiuxetan, conventional therapy can be used safely and
effectively. This has been confirmed in retrospective
studies of patients after 90Y-ibritumomab tiuxetan
therapy[15].
β-radiation emitted by 90Y has a path length of 5
mm, and therefore it causes no significant damage to
healthy tissues surrounding the tumour. Moreover, a low
range of radiation and a short half-life allow for the drug
to be administered on an out-patient basis.
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Figure 2. Regression of the involved lymph nodes in the CT scan of the
chest 4 months after treatment
The experience of administration of the 90Y-ibri-
tumomab tiuxetan to our patient seems to confirm high
effectiveness of radioimmunotherapy. Eight months after
therapy the patient is in partial remission. The patient
still has splenomegaly, though it is lesser than before
treatment, but the systemic symptoms of the disease have
disappeared and complete regression of the enlarged
lymph nodes was observed. The side effects include
pancytopenia requiring red blood cell and platelet
transfusion, peripheral oedema and pain in the hand
joints.
We conclude that radioimmunotherapy is a new,
promising modality of treatment of non-Hodgkin’s
lymphomas, which combines the advantages of immuno-
therapy and radiotherapy with low toxicity for healthy
tissues and organs. Combination of monoclonal anti-
bodies with a radioisotope offers simultaneous irradiation
of disseminated lymphomas, which is of a special im-
portance in patients in advanced stages of the disease.
Introduction of new therapies, as well as attempts to
individualize the therapy in relation to the type of
lymphoma and risk factors, bring hopes for improving
the results of treatment of these malignancies.
Tomasz Wróbel MD, PhD
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